pmc logo image
The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481]
The FIELD Study Investigators
Cardiovasc Diabetol. 2004; 3: 9. Published online 2004 December 1. doi: 10.1186/1475-2840-3-9
PMCID:
PMC1129022
Abstract Full Text PDF–326K
 Is Cited by the Following 8 Articles in this Archive:
Impact of Fenofibrate on Type 2 Diabetes Patients with Features of the Metabolic Syndrome: Subgroup Analysis From FIELD
Michel P. Hermans
Curr Cardiol Rev. 2010 May; 6(2): 112–118. doi: 10.2174/157340310791162686
PMCID:
PMC2892076
Abstract Full Text PDF–224K
A Novel Method to Adjust Efficacy Estimates for Uptake of Other Active Treatments in Long-Term Clinical Trials
John Simes, Merryn Voysey, Rachel O'Connell, Paul Glasziou, James D. Best, Russell Scott, Christopher Pardy, Karen Byth, David R. Sullivan, Christian Ehnholm, Anthony Keech, for the FIELD Study Investigators
PLoS One. 2010; 5(1): e8580. Published online 2010 January 8. doi: 10.1371/journal.pone.0008580
Correction in:
PLoS One. 2010; 5(1): 10.1371/annotation/54433693-04e0-4f30-9a99-38fe3c5bb16b.
PMCID:
PMC2798963
Abstract Full Text PDF–256K Supplementary Material Correction
Effects of Long-Term Fenofibrate Treatment on Markers of Renal Function in Type 2 Diabetes: The FIELD Helsinki substudy
Carol Forsblom, Anne Hiukka, Eeva S. Leinonen, Jouko Sundvall, Per-Henrik Groop, Marja-Riitta Taskinen
Diabetes Care. 2010 February; 33(2): 215–220. Published online 2009 October 21. doi: 10.2337/dc09-0621
Correction in:
Diabetes Care. 2010 May; 33(5): 1151.
PMCID:
PMC2809252
Abstract Full Text PDF–441K Correction
Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial
Kushwin Rajamani, Peter G Colman, Li Ping Li, James D Best, Merryn Voysey, Michael C D'Emden, Markku Laakso, John R Baker, Anthony C Keech, on behalf of the FIELD study investigators
Lancet. 2009 May 23; 373(9677): 1780–1788. doi: 10.1016/S0140-6736(09)60698-X
PMCID:
PMC2687887
Abstract Full Text PDF–518K
Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
Russell Scott, Richard O'Brien, Greg Fulcher, Chris Pardy, Michael d'Emden, Dana Tse, Marja-Riitta Taskinen, Christian Ehnholm, Anthony Keech, on behalf of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators
Diabetes Care. 2009 March; 32(3): 493–498. doi: 10.2337/dc08-1543
PMCID:
PMC2646035
Abstract Full Text PDF–509K Supplementary Material
Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]
The FIELD Study Investigators
Cardiovasc Diabetol. 2005; 4: 13. Published online 2005 August 22. doi: 10.1186/1475-2840-4-13
PMCID:
PMC1266033
Abstract Full Text PDF–277K
Statins research unfinished saga: desirability versus feasibility
Enrique Z Fisman, Yehuda Adler, Alexander Tenenbaum
Cardiovasc Diabetol. 2005; 4: 8. Published online 2005 June 7. doi: 10.1186/1475-2840-4-8
PMCID:
PMC1156921
Abstract Full Text PDF–262K
Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both?
Alexander Tenenbaum, Enrique Z Fisman
Cardiovasc Diabetol. 2004; 3: 10. Published online 2004 December 1. doi: 10.1186/1475-2840-3-10
PMCID:
PMC538252
Abstract Full Text PDF–237K
You are here: NCBI > Literature > PubMed Central
Write to the Help Desk